PATH vs RAPT · P/E 19, rev $1.61B vs $132.1M cap
Uipath Inc (PATH) versus RAPT Therapeutics Inc (RAPT) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
RAPT Therapeutics Inc (RAPT) is a biotechnology company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported RAPT revenue for 2023-12-31 was $0. Net income was -$116.8M. Revenue was down 100.0% from 2022-12-31 to 2023-12-31. RAPT currently screens at market cap $132.1M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. RAPT currently screens at market cap $132.1M.
Not investment advice. Open the PATH and RAPT stock pages for the full models.
Not investment advice.